Skip to main content
Premium Trial:

Request an Annual Quote

Correction: Jun 15, 2004


In the 6-08-04 issue of Inside Bioassays, the article “MIT’s Anne Carpenter Discusses HT Microscopy, Cellular Arrays” (see InsideBioassays, 6/8/2004) contained an error in the headline and the story. Carpenter is a postdoctoral researcher at the Whitehead Institute, not at MIT as the story stated. While David Sabatini, the professor in whose laboratory she works, is a professor both at Whitehead and MIT, Carpenter is employed through the Whitehead.

In the 6-08-04 issue of Inside Bioassays, the article, “Now on Its Own, Pharmacopeia Drug Discovery to “Ramp up” Internal Efforts” (see InsideBioassays, 6/8/2004) contains a factual error. The article, based on incomplete facts provided, stated that the company has a cash burn of $46 million. In fact, PDD has $46 million in cash and its expected burn is less than $5 million, according to the company.


The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.